[1] 中华医学会核医学分会.  131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
Chinese Society of Nuclear Medicine.  Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218-241.   doi: 10.3760/cma.j.cn321828-20201113-00412
[2] Haugen BR, Alexander EK, Bible KC, et al.  2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[3] Dehbi HM, Mallick U, Wadsley J, et al.  Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(1): 44-51.   doi: 10.1016/S2213-8587(18)30306-1
[4] Schlumberger M, Leboulleux S, Catargi B, et al.  Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial[J]. Lancet Diabetes Endocrinol, 2018, 6(8): 618-626.   doi: 10.1016/S2213-8587(18)30113-X
[5] Fallahi B, Beiki D, Takavar A, et al.  Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial[J]. Nucl Med Commun, 2012, 33(3): 275-282.   doi: 10.1097/MNM.0b013e32834e306a
[6]

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J/OL]. Control Clin Trials, 1996, 17(1): 1–12[2023-03-22]. https://www.sciencedirect.com/science/article/abs/pii/0197245695001344?via%3Dihub. DOI: 10.1016/0197-2456(95)00134-4.
[7]

Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi[J/OL]. Thyroid Res, 2010, 3(1): 9[2023-03-22]. https://thyroidresearchjournal.biomedcentral.com/articles/10.1186/1756-6614-3-9. DOI: 10.1186/1756-6614-3-9.
[8] Ma C, Feng F, Wang SY, et al.  Chinese data of efficacy of low- and high-dose iodine-131 for the ablation of thyroid remnant[J]. Thyroid, 2017, 27(6): 832-837.   doi: 10.1089/thy.2015.0658
[9] Ahtiainen V, Vaalavirta L, Tenhunen M, et al.  Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up[J]. Acta Oncol, 2020, 59(9): 1064-1071.   doi: 10.1080/0284186X.2020.1785003
[10] Dong P, Qu Y, Yang L, et al.  Outcomes after radioiodine ablation in patients with thyroid cancer: long-term follow-up of a Chinese randomized clinicaltrial[J]. Clin Endocrinol (Oxf), 2021, 95(5): 782-789.   doi: 10.1111/cen.14563
[11]

Mäenpää HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study[J/OL]. PLoS One, 2008, 3(4): e1885[2023-03-22]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001885. DOI: 10.1371/journal.pone.0001885.
[12] James DL, Ryan ÉJ, Davey MG, et al.  Radioiodine remnant ablation for differentiated thyroid cancer: a systematic review and meta-analysis[J]. JAMA Otolaryngol Head Neck Surg, 2021, 147(6): 544-552.   doi: 10.1001/jamaoto.2021.0288
[13] Song XH, Meng ZW, Jia Q, et al.  Different radioiodine dose for remnant thyroid ablation in patients with differentiated thyroid cancer: a meta-analysis[J]. Clin Nucl Med, 2015, 40(10): 774-779.   doi: 10.1097/RLU.0000000000000914
[14]

Vardarli I, Weidemann F, Aboukoura M, et al. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis[J/OL]. BMC Cancer, 2020, 20(1): 550[2023-03-22]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07029-3. DOI: 10.1186/s12885-020-07029-3.
[15] Schlumberger M, Catargi B, Borget I, et al.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1663-1673.   doi: 10.1056/NEJMoa1108586
[16] Mallick U, Harmer C, Yap B, et al.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1674-1685.   doi: 10.1056/NEJMoa1109589